-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Raises Price Target to $22

Benzinga·12/16/2025 13:49:25
语音播报
Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and raises the price target from $13 to $22.